Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
JUBILANT On Other Exchanges
Symbol
Exchange
JUBILANT is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

jubilant life sciences ltd (JUBILANT) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JUBILANT LIFE SCIENCES LTD (JUBILANT)

Related News

No related news articles were found.

jubilant life sciences ltd (JUBILANT) Related Businessweek News

No Related Businessweek News Found

jubilant life sciences ltd (JUBILANT) Details

Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company, manufactures and supplies pharmaceutical and life sciences products and services worldwide. The company provides active pharmaceutical ingredients (APIs) for cardiovascular system (CVS) and central nervous system (CNS), as well as anti-infective and anti-ulcerants. Its APIs include solid dosage formulations for CVS, CNS, and anti-allergy categories; radiopharmaceuticals for the diagnosis, treatment, and monitoring of diseases; and allergy therapy products, including allergenic extracts and mixes, and skin test devices. The company also offers life sciences ingredients, such as pyridine and picoline; fine chemicals; crop science chemicals; nutrition products, including niacinamide, niacin (vitamin B3), and choline chloride; animal nutrition products in the category of vitamin and mineral premixes, betaine, acidifiers, toxin binders, growth promoters, and emulsifiers; acetyl products, which include acetic acid, monochloro acetic acid, acetic anhydride, ethyl acetate, and sodium mono chlor acetate; and specialty gases, such as liquid carbon dioxide and ethylene oxide mixtures. In addition, it provides contract manufacturing services in manufacturing sterile injectables, and solid and semi solid dosage forms; drug discovery services in bioinformatics, chemoinformatics, and crystallography structure directed molecular design and information technology; pre clinical services, such as medicinal chemistry, analytical chemistry, custom synthesis, library design, and clinical development and market launch services; and conducts integrated drug discovery and development programs on oncology, metabolic disorders, pain, and inflammation. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. Jubilant Life Sciences Limited was incorporated in 1978 and is based in Noida, India.

6,100 Employees
Last Reported Date: 05/12/15
Founded in 1978

jubilant life sciences ltd (JUBILANT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jubilant life sciences ltd (JUBILANT) Key Developments

Jubilant Life Sciences Limited Receives ANDA approval for Levofloxacin Tablets

Jubilant Life Sciences Ltd, has received Abbreviated New Drug Application (ANDA) final approval from the U.S. Food and Drug Administration (US FDA) for Levofloxacin Tablets, 250mg and 500mg, the generic version of Levaquin Tablets(of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax. The total market size for Levofloxacin Tablets as per IMS is $28 Million per annum.

Jubilant Life Sciences Limited expected to report Q1 2016 results on July 30, 2015. This event was calculated by Capital IQ (Created on May 26, 2015).

Jubilant Life Sciences Limited expected to report Q1 2016 results on July 30, 2015. This event was calculated by Capital IQ (Created on May 26, 2015).

Jubilant Life Sciences Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015; Provides Earnings Guidance for the Year 2016

Jubilant Life Sciences Limited reported audited standalone and consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 7,156.3 million compared to INR 9,599.2 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 242.7 million compared to INR 727.9 million for the same period a year ago. Loss from ordinary activities before tax was of INR 2,209.1 million compared to income of INR 490.1 million for the same period a year ago. Net loss was INR 2,068.9 million or INR 12.99 per diluted share compared to net profit of INR 207.6 million or INR 1.30 per diluted share for the same period a year ago. For the year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 31,406.2 million compared to INR 36,275.1 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 1,687.6 million compared to INR 4,064.1 million for the same period a year ago. Profit from ordinary activities before tax was of INR 2,463 million compared to INR 681.6 million for the same period a year ago. Net profit was INR 2,051.1 million or INR 12.88 per diluted share compared to INR 8.2 million or INR 0.05 per diluted share for the same period a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 15,232.5 million compared to INR 15,516.2 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 1,812.3 million compared to INR 1,771.6 million for the same period a year ago. Profit from ordinary activities before tax was of INR 677.9 million compared to of INR 1,435.9 million for the same period a year ago. Net profit after taxes, minority interest and share of profit /loss of associates was INR 427.3 million or INR 2.68 per diluted share compared to INR 988.1 million or INR 6.20 per diluted share for the same period a year ago. EBITDA of INR 2,530 million. For the year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 57,761.4 million compared to INR 57,216.1 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 4,013.1 million compared to INR 7,264.3 million for the same period a year ago. Profit from ordinary activities before tax was of INR 403.2 million compared to of INR 2,072.8 million for the same period a year ago. Net loss after taxes, minority interest and share of profit /loss of associates was INR 577.6 million or INR 3.63 per diluted share compared to INR 1,090.4 million or INR 6.85 per diluted share for the same period a year ago. EBITDA at INR 7,320 million. The total CapEx stood at INR 2,500 million and the product development expenditure of INR 1,050 million. In fiscal year 2016, revenue growth is expected to be driven by Pharmaceuticals segment primarily led by improved performance in Radiopharmaceuticals, normalization of CMO business operations and growth in generics business through new product and new market launches. Life Science Ingredients segment is expected to deliver better results due to improved operational efficiency and growth in Nutritional Products and Fine Ingredients businesses. The company expects a strong recovery in fiscal year 2016 both in the top line and bottom line.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JOL:IN 265.25 INR +2.35

JUBILANT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 210.20 INR +1.00
Glenmark Pharmaceuticals Ltd 1,016 INR +59.90
Piramal Enterprises Ltd 916.95 INR +15.30
Shasun Pharmaceuticals Ltd 389.50 INR +4.95
Torrent Pharmaceuticals Ltd 1,442 INR +5.75
View Industry Companies
 

Industry Analysis

JUBILANT

Industry Average

Valuation JUBILANT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 1.7x
Price/Cash Flow 17.8x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUBILANT LIFE SCIENCES LTD, please visit www.jubl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.